| ID | 1033 |
| Name of the vaccine | Adacel Polio |
| Microbe | Bacteria |
| Disease name | Diphtheria |
| Name of bacteria | Corynebacterium diphtheriae |
| Type of vaccine | Combination |
| Nucleic acid content | DNA |
| Age | 4 years and older |
| Description of the vaccine | Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed combined with inactivated poliomyelitis vaccine. |
| Name of the manufacturer | Sanofi Pasteur Limited |
| Name of the manufacturing country | Canada |
| Year of manufacture | 2013 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-positive bacillus. |
| Efficacy | 83.8% of adults, 97.1% of adolescents and at least 97.6% of children achieved a seroprotective antitoxin level of 0.1 IU/mL. |
| Vaccine formulation | Suspension for injection |
| Dosage | Single dose of 0.5 mL. |
| Mechanism of action | Serum diphtheria antitoxin level:
0.01 IU/mL : Lowest protection
at least 0.1 IU/mL : Protective |
| Route of administration | Intramuscular |
| Indications | Immunization against tetanus, diphtheria, pertussis and poliomyelitis. |
| Export | NA |
| Approval | NA |
| Adjuvant | Aluminium phosphate |
| Repurposing | For tetanus, pertussis and poliomyelitis. |
| Side effects of vaccine | Redness, swelling, pain, tired, headache, generalized body ache and sore or swollen joints. |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://pdf.hres.ca/dpd_pm/00021710.PDF |
| Other name | NA |
| Additional Links | https://www.toronto.ca/community-people/health-wellness-care/diseases-medications-vaccines/diphtheria-tetanus-pertussis-and-polio-vaccines/
|